Phase 2 N=296 Prevention

Bevacizumab Against Recurrent Retinal Detachment

Retinal Detachment · Proliferative Vitreoretinopathy

Bottom Line

View on ClinicalTrials.gov: NCT02192970 ↗

Enrolled (actual)

296

Serious AEs

0.0%

Results posted

Mar 2021

Primary outcome: Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Bevacizumab (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Wisconsin, Madison
Primary completion: Nov 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery	92; 169	—
SECONDARY Number of Participants (or Chart Reviews) With Presence of Proliferative Vitreoretinopathy	9; 26	—

Summary

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Eligibility Criteria

Inclusion Criteria

Age ≥ 18 years
Eyes with rhegmatogenous retinal detachment

Exclusion Criteria

Presence of PVR
Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.
Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
Secondary retinal detachment repair
Use of silicone oil as tamponade agent
Patients less than 18 years of age
Pregnancy
Known allergy or contraindication to intravitreal bevacizumab

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02192970). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.